Paller, Amy http://orcid.org/0000-0001-6187-6549
Jaworski, Jennifer C.
Simpson, Eric L.
Boguniewicz, Mark
Russell, John J.
Block, Julie K.
Tofte, Susan
Dunn, Jeffrey D.
Feldman, Steven R.
Clark, Adele R.
Schwartz, Gene
Eichenfield, Lawrence F.
Article History
First Online: 30 August 2018
Compliance with Ethical Standards
:
: This article was conceived during a 2013 roundtable in which all authors were engaged. The roundtable was supported by Valeant Pharmaceuticals North America LLC; however, there was no funding source for writing this article.
: Amy Paller is a principal investigator without personal compensation for atopic dermatitis clinical trials with Incyte, LEO Pharma, and Sanofi-Regeneron, and served as a consultant for AbbVie, Dermira, Eli Lilly, Expanscience, GSK-Stiefel, Menlo Therapeutics, Novartis, Pfizer, Sanofi-Regeneron, and Valeant. Jennifer C. Jaworski was a full-time employee of Prescott Medical Communications Group, which received financial compensation for organizing the 2013 roundtable at which this manuscript was conceived. Eric L. Simpson is an investigator for AbbVie, Anacor (now part of Pfizer), Celgene, Dermira, Eli Lilly, Galderma, Genentech, LEO Pharma, Menlo Therapeutics, Pfizer, Regeneron, and Sanofi, and has served as a consultant for Amgen, Anacor, Chugai, Eli Lilly, GlaxoSmithKline, LEO Pharma, Novartis, Regeneron, Roivant, Tioga, and Vanda. Mark Boguniewicz has received research grants from Anacor (now part of Pfizer) and Regeneron, and has served as a consultant for Valeant, Pfizer, Regeneron, and Sanofi-Genzyme. John J. Russell has served as a consultant and a Speakers Bureau member for Sanofi-Aventis. Julie K. Block is a salaried executive of National Eczema Association, which has received grants and sponsorship awards from a variety of industry partners including Valeant (full list at: ExternalRef removed). Susan Tofte has served as a consultant for Valeant and as an Advisory Board member for Amgen, Johnson & Johnson Consumer & Personal Products Worldwide, Novartis, Sanofi-Regeneron, Pfizer, and LEO Pharma. Steven R. Feldman has served as a consultant for AbbVie, Boehringer Ingelheim, Celgene, Ely Lilly, Galderma, Janssen, LEO Pharma, Pfizer, Mylan, Novartis, Qurient, and Samsung, and a Speakers Bureau member for AbbVie, Celgene, Janssen, Eli Lilly, Novartis, and Ortho Dermatologics (formerly Valeant). He has received grants from Pfizer, Sanofi, Regeneron, AbbVie, Celgene, Novartis, and Eli Lilly. Steven R. Feldman is a founder and part owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment. Adele R. Clark has been a sub-investigator without personal compensation for Astellas, Medicis (now part of Valeant), Galderma, Anacor (now part of Pfizer), GSK-Stiefel, Maruho, Merz, Regeneron, and HanAll Biopharma. She has received financial compensation for her work as a consultant for Valeant Pharmaceuticals North America LLC. Lawrence Eichenfield has been a principal investigator for Astellas, Galderma, and GSK-Stiefel. He has received compensation for his work as a consultant for Valeant, Anacor (now part of Pfizer), Galderma, Promius GSK-Stiefel, and TopMD. Jeffrey D. Dunn and Gene Schwartz have no conflicts of interest that are directly relevant to the content of this article.